Fathom Therapeutics Raises $47 Million to Advance AI Drug Design Platform

April 28, 2026
Fathom Therapeutics, formerly Atommap Corp., has secured $47 million in an oversubscribed Series A round led by Sutter Hill Ventures. The company uses quantum chemistry and AI through its Microcosmos platform to design small molecule drugs and will use the funds to expand lab and discovery programs.

Fathom Therapeutics, formerly Atommap Corp., has raised $47 million in an oversubscribed Series A financing led by Sutter Hill Ventures, announced in a press release.

The company applies quantum chemistry and artificial intelligence to design small molecule drugs. Its Microcosmos platform simulates protein dynamics to identify molecules with therapeutic potential.

Funding from the Series A round will be used to strengthen laboratory capabilities and expand discovery programs. Fathom has also appointed Mandana Honu as Chief Business Officer and added Diala Ezzeddine to its board of directors.

We hope you enjoyed this article.

Subscribe to AI Funding Brief

Market report

AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation

ModelOp

The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.

Read more